• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型高通量、平行感染测定法,用于测定苏黎世原发性 HIV-1 感染研究中 346 株原发性 HIV-1 分离株在原代细胞中的复制能力。

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

机构信息

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, 8091 Zürich, Switzerland.

Institute of Medical Virology, University of Zürich, 8057 Zürich, Switzerland.

出版信息

Viruses. 2021 Mar 4;13(3):404. doi: 10.3390/v13030404.

DOI:10.3390/v13030404
PMID:33806576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8000554/
Abstract

HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have been established. However, there is still demand for a high throughput replication capacity assay using primary cells which is robust and reproducible. In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSF and HIV-1 JR-CSF. Replication capacity was determined by measuring the viral growth on PBMCs over 10 days by longitudinally transferring cell culture supernatant to TZM-bl reporter cells. By utilizing the TZM-bl luciferase reporter assay, we determined replication capacity by measuring viral infectivity. The simplicity of the experimental setup allowed for all 346 primary HIV-1 isolates to be replicated at one time. Although the infectious input dose for each virus was normalized, a broad range of replication capacity values over 4 logs was observed. The approach was confirmed by two repeated experiments and we demonstrated that the reproducibility of the replication capacity values is statistically comparable between the two separate experiments. In summary, these results endorse our high throughput replication capacity assay as reproducible and robust and can be utilized for large scale HIV-1 replication capacity experiments in primary cells.

摘要

HIV-1 复制能力是理解单变体或病毒群体复制能力的重要特征。它可以进一步帮助理解 HIV-1 的致病性、疾病进展和耐药突变。为了有效地研究 RC,已经建立了许多检测方法。然而,仍然需要一种使用原代细胞的高通量复制能力检测方法,该方法具有稳健性和可重复性。在本研究中,我们建立了这样一种检测方法,并使用来自苏黎世原发性 HIV 感染研究 (ZPHI) 中招募的 346 例原发性 HIV-1 分离株和两种对照病毒 HIV-1 JR-CSF 和 HIV-1 JR-CSF 对其进行了验证。通过在 10 天内纵向将细胞培养上清液转移到 TZM-bl 报告细胞中来测量 PBMC 上的病毒生长,从而确定复制能力。通过利用 TZM-bl 荧光素酶报告检测,我们通过测量病毒感染力来确定复制能力。实验设置的简单性允许同时复制所有 346 例原发性 HIV-1 分离株。尽管每个病毒的感染输入剂量都进行了归一化,但观察到复制能力值在 4 个对数范围内的广泛范围。通过两次重复实验证实了该方法,并且我们证明了两个单独实验之间复制能力值的重现性在统计学上是可比的。总之,这些结果支持我们的高通量复制能力检测方法具有可重复性和稳健性,可用于原代细胞中的大规模 HIV-1 复制能力实验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/8853f7395d9d/viruses-13-00404-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/06dfd42a49d0/viruses-13-00404-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/f9bc50ad1cf2/viruses-13-00404-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/67f2dc7651b2/viruses-13-00404-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/3e76f0b819a8/viruses-13-00404-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/8853f7395d9d/viruses-13-00404-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/06dfd42a49d0/viruses-13-00404-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/f9bc50ad1cf2/viruses-13-00404-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/67f2dc7651b2/viruses-13-00404-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/3e76f0b819a8/viruses-13-00404-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cf/8000554/8853f7395d9d/viruses-13-00404-g005.jpg

相似文献

1
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.一种新型高通量、平行感染测定法,用于测定苏黎世原发性 HIV-1 感染研究中 346 株原发性 HIV-1 分离株在原代细胞中的复制能力。
Viruses. 2021 Mar 4;13(3):404. doi: 10.3390/v13030404.
2
Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.开发一种基于荧光素酶的病毒抑制测定法,以评估疫苗诱导的 CD8 T 细胞应答。
J Immunol Methods. 2014 Jul;409:161-73. doi: 10.1016/j.jim.2013.11.021. Epub 2013 Nov 28.
3
Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.原发性感染期间分离出的耐药性1型人类免疫缺陷病毒变体的传染性和复制能力。
J Virol. 2003 Jul;77(14):7736-45. doi: 10.1128/jvi.77.14.7736-7745.2003.
4
Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.急性感染期病毒的复制能力推动HIV-1疾病进展。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.01806-16. Print 2017 Apr 15.
5
Impaired replication capacity of acute/early viruses in persons who become HIV controllers.急性/早期病毒复制能力受损的人成为 HIV 控制器。
J Virol. 2010 Aug;84(15):7581-91. doi: 10.1128/JVI.00286-10. Epub 2010 May 26.
6
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.从抗逆转录病毒治疗失败患者中分离出的HIV毒株的复制能力、生物学表型及耐药性
J Med Virol. 2003 Jan;69(1):1-6. doi: 10.1002/jmv.10269.
7
Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity.母婴传播的HIV瓶颈效应选择了具有较低Gag蛋白酶驱动复制能力的一致病毒。
J Virol. 2017 Aug 10;91(17). doi: 10.1128/JVI.00518-17. Print 2017 Sep 1.
8
Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.Gag蛋白酶驱动的复制能力的亚型特异性差异与HIV-1疾病进展中的亚型间差异一致。
J Virol. 2017 Jun 9;91(13). doi: 10.1128/JVI.00253-17. Print 2017 Jul 1.
9
Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells.在一项由血液来源的巨噬细胞和外周血单核细胞组成的自体原代细胞检测中,对HIV-1进行的初步体外生长周期及传播研究。
Virology. 1996 Dec 15;226(2):205-16. doi: 10.1006/viro.1996.0648.
10
Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.聚合酶驱动的复制能力影响 HIV-1 型 C 亚型感染的疾病进展。
J Virol. 2018 Sep 12;92(19). doi: 10.1128/JVI.00811-18. Print 2018 Oct 1.

引用本文的文献

1
QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro.QuickFit:一种高通量基于 RT-qPCR 的检测方法,用于定量体外病毒生长和适应性。
Viruses. 2024 Aug 19;16(8):1320. doi: 10.3390/v16081320.
2
The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.TZM-bl 报告细胞系表达犬尿氨酸酶,可中和 HIV-1 中和测定中的 2F5 样抗体。
Int J Mol Sci. 2022 Jan 7;23(2):641. doi: 10.3390/ijms23020641.

本文引用的文献

1
HIV-1 Sequences from Ugandan Early Infections Reveal Sequence Variants Associated with Elevated Replication Capacity.来自乌干达早期感染者的 HIV-1 序列显示与高复制能力相关的序列变异。
Viruses. 2021 Jan 23;13(2):171. doi: 10.3390/v13020171.
2
Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.聚合酶驱动的复制能力影响 HIV-1 型 C 亚型感染的疾病进展。
J Virol. 2018 Sep 12;92(19). doi: 10.1128/JVI.00811-18. Print 2018 Oct 1.
3
Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
通过系统发生动力学量化 HIV-1 耐药突变的适应代价。
PLoS Pathog. 2018 Feb 20;14(2):e1006895. doi: 10.1371/journal.ppat.1006895. eCollection 2018 Feb.
4
Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.Gag蛋白酶驱动的复制能力的亚型特异性差异与HIV-1疾病进展中的亚型间差异一致。
J Virol. 2017 Jun 9;91(13). doi: 10.1128/JVI.00253-17. Print 2017 Jul 1.
5
Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.急性感染期病毒的复制能力推动HIV-1疾病进展。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.01806-16. Print 2017 Apr 15.
6
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.对1型干扰素的抗性是HIV-1传播适应性的主要决定因素。
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E590-E599. doi: 10.1073/pnas.1620144114. Epub 2017 Jan 9.
7
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs.追踪HIV-1传播:HIV-1传播者与接受者配对的包膜特征
Retrovirology. 2016 Sep 5;13(1):62. doi: 10.1186/s12977-016-0299-0.
8
Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance.C型HIV-1的异性传播选择了类似共识的变体,但其复制能力或对α干扰素的抗性并未增加。
PLoS Pathog. 2015 Sep 17;11(9):e1005154. doi: 10.1371/journal.ppat.1005154. eCollection 2015 Sep.
9
Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds.与适应性代价和病毒基因背景相关的传播型HIV-1耐药突变的持续性。
PLoS Pathog. 2015 Mar 23;11(3):e1004722. doi: 10.1371/journal.ppat.1004722. eCollection 2015 Mar.
10
A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.一种新型急性逆转录病毒综合征严重程度评分可预测HIV-1疾病进展的关键替代标志物。
PLoS One. 2014 Dec 9;9(12):e114111. doi: 10.1371/journal.pone.0114111. eCollection 2014.